EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol)

Seyed Alireza Mirhosseini iD, Mohammadreza Akbari, Davar Aldavood, Hooyar Zarifkar, Armin Attar iD, Javad Kojuri iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0325663 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS One, 2025. Verfasst von Seyed Alireza Mirhosseini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, TAHA Clinical Trial Group, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Ticagrelor, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the wide variety of antiplatelet regimens and durations, the optimal treatment approach for chronic coronary syndrome (CCS) patients remains a subject of ongoing debate. While current guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, the development of drug-eluting stents (DES) and more potent agents has sparked interest in shorter DAPT regimens, followed by P2Y12 inhibitor monotherapy, as a potential alternative. Recent trials and meta-analyses have shown that this approach may provide similar protection against thrombotic events with reduced bleeding risk. Despite promising data, the safety and efficacy of Ticagrelor monotherapy specifically in CCS patients have not been rigorously tested in randomized trials.

Methods

TICALONE is a non-inferiority, two-arm, double-blinded, randomized controlled clinical trial designed to evaluate the safety and efficacy of ticagrelor monotherapy compared to DAPT in CCS patients following PCI. Eligible patients undergoing PCI with drug-eluting stents will be randomly assigned to receive either conventional DAPT (aspirin and clopidogrel) or ticagrelor monotherapy for six months. Follow-up visits will be conducted at 1, 3, 6, and 12 months post-PCI to assess efficacy and safety endpoints. The primary efficacy endpoint is a composite endpoint of cardiac death, myocardial infarction, stroke, stent thrombosis, and the need for revascularization. The primary safety endpoint is the occurrence of Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding events. The secondary endpoints include components of the primary efficacy endpoint, any bleeding event (BARC type 1–5), and all-cause mortality. Ancillary endpoints are other adverse events including dyspnea, drug adherence, and reaction. All endpoints will be monitored by a Data Safety Monitoring Board (DSMB) and Trial Management Committee (TMC). Statistical analysis and reporting of trial results will follow the estimand framework. Kaplan-Meier estimates will be used to assess event rates, while the log-rank test and Cox regression analysis will be employed to compare safety and efficacy outcomes between the groups.

Discussion

This trial may serve as a crucial step toward eliminating aspirin from post-PCI regimens, specifically in CCS patients. By comparing the safety and efficacy of Ticagrelor monotherapy with the conventional DAPT regimen and addressing potential risks of aspirin-free therapy and adverse events like dyspnea, this study could offer valuable insights into the possibility of P2Y12 monotherapy’s safe adoption in this population.

Trial registration

TICALONE is registered at https://clinicaltrials.gov/ with the identifier NCT06509893.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorPlatelet Aggregation InhibitorsPercutaneous Coronary InterventionDual Anti-Platelet TherapyHumansClopidogrelFemaleMaleDrug-Eluting StentsDouble-Blind MethodAspirinTreatment OutcomeMiddle AgedAgedRandomized Controlled Trials as TopicHemorrhageEquivalence Trials as Topic

Substanzen

TicagrelorPlatelet Aggregation InhibitorsClopidogrelAspirin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, TAHA Clinical Trial Group, Shiraz University of Medical Sciences, Shiraz, Iran.
  • MD-MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Seyed Alireza Mirhosseini, Armin Attar, Javad Kojuri

Förderung

  • Shiraz University of Medical Sciences

Zitieren

APA

Mirhosseini, S. A., Akbari, M., Aldavood, D., Zarifkar, H., Attar, A., & Kojuri, J. (2025). Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol). PLOS One. https://doi.org/10.1371/journal.pone.0325663

Vancouver

Mirhosseini SA, Akbari M, Aldavood D, Zarifkar H, Attar A, Kojuri J. Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol). PLOS One. 2025. doi:10.1371/journal.pone.0325663

BibTeX
@article{Mirhosseini2025,
  author = {Mirhosseini, Seyed Alireza and Akbari, Mohammadreza and Aldavood, Davar and Zarifkar, Hooyar and Attar, Armin and Kojuri, Javad},
  title = {Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol)},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325663}
}
Kostenlos starten →